

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>				Docket Number (Optional) TUU-P01-006	O I P E SC 53 MAR 04 2002 P A T E N T D O C U M E N T S T R A D E M A R K S E R I E S	Application Number 09/628,225
				Applicant Bacovchin et al.		
				Filing Date July 28, 2000		Group Art Unit 659
<b>U.S. PATENT DOCUMENTS</b>						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA 6,011,155	1/4/00	Villhauer			TECH CENTER 1600 2900
BR	AB 5,834,428	11/10/98	Drucker	514	12	MAR 14 2002
BR	AC 5,631,224	5/20/97	Efendic et al.			
BR	AD 5,061,811	10/29/91	Pinori et al.	517	277	
BR	AE 4,522,752	6/11/85	Sisto et al.	530	314	
<b>FOREIGN PATENT DOCUMENTS</b>						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES      NO
	AF WO 98/25644	6/18/98	PCT			
BR	AG WO 97/40832	11/6/97	PCT			
	AH WO 95/15309	6/8/95	PCT			
	AI WO 93/08259	4/29/93	PCT			
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages Etc.)</i>						
	AJ	Bell et al., 1983, "Exon duplication and divergence in the human preproglucagon gene". Nature 304(5924):368-71				
	AK	Bell et al., 1983, "Hamster preproglucagon contains the sequence of glucagon and two related peptides", Nature 302(5910):716-8				
	AL	Conlon, 1988, "Proglucagon-derived peptides: nomenclature, biosynthetic relationships and physiological roles", Diabetologia 31(8):563-6				
	AM	Coruzzi et al., 1989, "Gastric antisecretory activity of telenzepine, a new M1-selective muscarinic antagonist: comparison with pirenzepine", Arch Int Pharmacodyn Ther 302:232-41				
	AN	Deacon et al., 1995, "Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH <sub>2</sub> -terminus in type II diabetic patients and in healthy subjects", Diabetes 44(9):1126-31				
	AO	Dupre, 1991, "Influences of the gut on the endocrine pancreas" The Endocrine Pancreas (Raven Press, New York) pp 253-281				
	AP	Ebert et al., 1987, "Gastrointestinal peptides and insulin secretion", Diabetes Met. Rev. 3:1-26				
	AQ	Gutniak et al., 1992, "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus", N Engl J Med 326(20):1316-22				
	AR	Habener et al., 1991, "Biosyntheses of glucagon" The Endocrine Pancreas (Raven Press, New York) pp. 53-71				
	AS	Holst et al., 1987, "Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut", FEBS Lett. 211(2):169-74				

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)		Docket Number (Optional) TUU-P01-006	Application Number 09/628,225
		Applicant Bacochin et al.	OIF MAR 8 4 2002 JC53 PATENT & TRADEMARK OFFICE Group Art Unit 1657
		Filing Date July 28, 2000	
BR	AT	Kawashima et al., 1990, "Pharmacological differentiation of presynaptic muscarinic receptors modulating acetylcholine release from postsynaptic muscarinic receptors in guinea-pig ileum", Gen Pharmacol 21(1):17-21	
BR	AU	Kinder et al., 1985, "Acylamino boronic acids and difluoroborane analogues of amino acids: potent inhibitors of chymotrypsin and elastase", J Med Chem 28(12):1917-25	
BR	AV	Kreymann et al., 1987, "Glucagon-like peptide-1 7-36: a physiological incretin in man", Lancet 2(8571):1300-4	
BR	AW	Kubiak et al., 1994, "Metabolism of mouse growth hormone-releasing factor, mGRF(1-42)OH, and selected analogs from the hGRF series in mouse and bovine plasma in vitro", Pept Res 7(3):153-61	
BR	AX	Lambrecht et al., 1989, "Pharmacology of hexahydro-difenidol, hexahydro-sila-difenidol and related selective muscarinic antagonists", Trends Pharmacol Sci 10(Suppl):60	
BR	AY	Lund et al., 1982, "Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem", Proc Natl Acad Sci U S A79(2):345-9	
BR	AZ	Matteson et al., 1984, "Synthesis and properties of pinanediol $\alpha$ -amino boronic acids", Organometallics 3:1284	
BR	BA	Mojsov et al., 1986, "Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing", J Biol Chem 261(25):11880-9	
BR	BB	Mojsov et al., 1987, "Insulinotropin: glucagon-like peptide 1 (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas", J Clin Invest 79(2):616-9	
BR	BC	Mojsov, 1992, "Structural requirements for biological activity of glucagon-like peptide-1", Int J Pept Protein Res 40(3-4):333-43	
BR	BD	Orskov et al., 1987, "Pancreatic and intestinal processing of proglucagon in man", Diabetologia 30(11):874-81	
BR	BE	Patzelt et al., 1979, "Identification and processing of proglucagon in pancreatic islets", Nature 282(5736):260-6	
BR	BF	Pospisilik, John A. et al. Metabolism of Glucagon by Dipeptidyl Peptidase IV (CD26). <i>Regulatory Peptides</i> 96, 133-141 (2001).	
BR	BG	Radhakrishna et al., 1979, "New method for direct conversion of amides to amines", J Org Chem 44:1746	
BR	BH	Schmidt et al., 1985, "Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets", Diabetologia 28(9):704-7	
BR	BI	Shue et al., 1987, "Amide bond surrogates: a general synthetic route to trans carbon-carbon double bond isosteres", Tetrahedron Letters 28:3225	
BR	BJ	Stanley et al., 1989, "Repeated hypothalamic stimulation with neuropeptide Y increases daily carbohydrate and fat intake and body weight gain in female rats", Physiol Behav 46(2):173-7	



TECH CENTER 1600-800

MAR 14 2002

RECEIVED

Jeffrey E. Russel

Apr 1 22 2003

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION</b> <b>IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>			Docket Number (Optional) TUU-P01-006	Application Number 09/628,225
			Applicant Bacochin et al.	
			Filing Date July 28, 2000	Group Art Unit
 	BK	Weir et al., 1989, "Glucagonlike peptide I (7-37) actions on endocrine pancreas", Diabetes 38(3):338-42		
	BL	Wilding et al., 1992, "Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats", J Endocrinol 132(2):299-304		
EXAMINER			DATE CONSIDERED <u>April 22, 2003</u>	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant				

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TECH CENTER 1600/290

M 7/24 2002

RECEIVED

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) TUU-P01-006	Application Number 09/628,225
		Applicant Bachovchin et al.	
		Filing Date July 28, 2000	Group Art Unit 1653

**U.S. PATENT DOCUMENTS**

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO
JKR	AA WO 98/19998	5/14/98	PCT			
JKR	AB WO 96/14857	5/23/96	PCT			
JKR	AC WO 89/03223	4/20/89	PCT			

**OTHER DOCUMENTS***(Including Author, Title, Date, Pertinent Pages Etc.)*

JKR	AD	Balkan et al. Improved insulin secretion and oral glucose tolerance after in vivo inhibition of DPP-IV in obese zucker rats. <i>Diabetologia Suppl. 40</i> , A131 Abstract (1997).
JKR	AE	Coutts et al. Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. I. Variation of the P2 Position of Xaa-boroPro Dipeptides. <i>J. Med. Chem.</i> 39, 2087-2094 (1996).
JKR	AF	Deacon et al. Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields an N-Terminally Truncated Peptide that is a Major Endogenous Metabolite in Vivo. <i>J. Clin. Endocrin.</i> 83, 952-957 (1995).
JKR	AG	Holst, J. J. & Deacon, C. F. Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes. <i>Diabetes</i> 47, 1663-1670 (1998).
JKR	AH	Kieffer et al. Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV. <i>Endocrin.</i> 136, 3585-3596 (1995).
JKR	AI	Mentlein et al. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagons-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. <i>Eur. J. Biochem.</i> 214, 829-835 (1993).
JKR	AJ	Mentlein et al. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. <i>Regulatory Peptides</i> 49, 133-144 (10 December 1993).
JKR	AK	Pederson et al. Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide. <i>Diabetes</i> 47, 1253-1258 (August 1998).

EXAMINER

Teffre, E. Russell

DATE CONSIDERED

April 21, 2003

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.